{"filings":[{"id":127745,"accession_number":"0001683168-25-008486","cik":1939937,"company_name":"Exousia Bio, Inc.","ticker":"LMMY","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","5.01","2.01","3.02","5.02","9.01"],"status":"ready","headline":"LAMY acquires Exousia Ai in reverse merger; appoints Matthew Dwyer as sole officer and director","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Exousia Ai, issuing 62,223,000 shares of common stock to Exousia Ai shareholders.","Zhang Shengwu resigned as sole officer/director; Matthew Dwyer appointed as replacement effective November 17, 2025.","Exousia Ai is a clinical-stage biotech developing plant-based exosome therapies, initially for oncology.","Exousia Ai received FDA Orphan Drug Designation in November 2025 for its exosome-based glioblastoma multiforme (GBM) treatment.","The Company adopts Exousia Ai's business plan and expects to use its proprietary exosome loading technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":34550000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197675,"accession_number":"0001683168-24-008767","cik":1939937,"company_name":"Exousia Bio, Inc.","ticker":"LMMY","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.01","5.02"],"status":"ready","headline":"Zhang Shengwu acquires 64.29% of LAMY, becomes sole director and CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zhang Shengwu purchased 5,250,000 shares (64.29% voting control) for $335,910 from Witmer and Townsend.","Dwight Witmer resigned as Director, CEO, CFO, Secretary; Stephen Townsend resigned as Director, COO.","Zhang Shengwu appointed as Sole Director, President, CEO, Secretary; will devote at least 20 hours/week.","Zhang Shengwu is CEO of Shanghai Jiuye Technology Group; former Director of Operations at Dalian Damao Surveying."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34550000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213899,"accession_number":"0001683168-24-006110","cik":1939937,"company_name":"Exousia Bio, Inc.","ticker":"LMMY","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"LAMY dismisses auditor Bush and Associates, appoints Boladale Lawal & Co effective immediately","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Bush and Associates CPA as independent auditor on July 23, 2024; no disagreements or reportable events.","Boladale Lawal & Co (Chartered Accountants) appointed as new auditor effective immediately.","Bush's reports on the Company's financial statements were unqualified; no disagreements on accounting principles or auditing scope."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":34550000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325142,"accession_number":"0001683168-23-001567","cik":1939937,"company_name":"Exousia Bio, Inc.","ticker":"LMMY","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LAMY appoints Stephen Townsend as COO; grants 250,000 shares as compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Townsend appointed as Chief Operating Officer, effective immediately, until March 2024 annual meeting.","Compensation consists of 250,000 shares of LAMY common stock for 12 months of service.","Townsend brings over 20 years of finance and real estate credit expertise to the role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":34550000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}